Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B.

Falcon BL, Pietras K, Chou J, Chen D, Sennino B, Hanahan D, McDonald DM.

Am J Pathol. 2011 Jun;178(6):2920-30. doi: 10.1016/j.ajpath.2011.02.019.

2.

Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.

Sennino B, Falcón BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM.

Cancer Res. 2007 Aug 1;67(15):7358-67.

3.

Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis.

Hosaka K, Yang Y, Seki T, Nakamura M, Andersson P, Rouhi P, Yang X, Jensen L, Lim S, Feng N, Xue Y, Li X, Larsson O, Ohhashi T, Cao Y.

Nat Commun. 2013;4:2129. doi: 10.1038/ncomms3129.

PMID:
23831851
4.

Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.

Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, McDonald DM.

Cancer Res. 2009 May 15;69(10):4527-36. doi: 10.1158/0008-5472.CAN-08-3779. Epub 2009 Apr 28.

5.

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK.

Cancer Biol Ther. 2010 Feb;9(3):176-82. Epub 2010 Feb 16.

6.

Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.

McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, Bucana C, Ellis LM.

J Clin Invest. 2007 Aug;117(8):2114-22.

7.

Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.

Pietras K, Pahler J, Bergers G, Hanahan D.

PLoS Med. 2008 Jan 29;5(1):e19. doi: 10.1371/journal.pmed.0050019.

8.

Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM.

J Clin Invest. 2006 Oct;116(10):2610-21.

9.

Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.

Yamaguchi SI, Ueki A, Sugihara E, Onishi N, Yaguchi T, Kawakami Y, Horiuchi K, Morioka H, Matsumoto M, Nakamura M, Muto A, Toyama Y, Saya H, Shimizu T.

Cancer Sci. 2015 Jul;106(7):875-82. doi: 10.1111/cas.12686. Epub 2015 May 26. Erratum in: Cancer Sci. 2015 Sep;106(9):1249.

10.

Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.

Sumida T, Kitadai Y, Shinagawa K, Tanaka M, Kodama M, Ohnishi M, Ohara E, Tanaka S, Yasui W, Chayama K.

Int J Cancer. 2011 May 1;128(9):2050-62. doi: 10.1002/ijc.25812.

11.

Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.

Kinoshita K, Nakagawa K, Hamada J, Hida Y, Tada M, Kondo S, Moriuchi T.

Int J Oncol. 2010 Oct;37(4):869-77.

PMID:
20811709
12.

Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.

Hasumi Y, Kłosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C.

Int J Cancer. 2007 Dec 15;121(12):2606-14.

13.

PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer.

Liu J, Liao S, Huang Y, Samuel R, Shi T, Naxerova K, Huang P, Kamoun W, Jain RK, Fukumura D, Xu L.

Clin Cancer Res. 2011 Jun 1;17(11):3638-48. doi: 10.1158/1078-0432.CCR-10-2456. Epub 2011 Apr 1.

14.

Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.

Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA.

Blood. 2013 Jun 27;121(26):5192-202. doi: 10.1182/blood-2013-03-490763. Epub 2013 Apr 30.

15.

Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.

Jain RK, Lahdenranta J, Fukumura D.

PLoS Med. 2008 Jan 29;5(1):e24. doi: 10.1371/journal.pmed.0050024. No abstract available.

16.

Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation.

Fuxe J, Tabruyn S, Colton K, Zaid H, Adams A, Baluk P, Lashnits E, Morisada T, Le T, O'Brien S, Epstein DM, Koh GY, McDonald DM.

Am J Pathol. 2011 Jun;178(6):2897-909. doi: 10.1016/j.ajpath.2011.02.008. Epub 2011 May 6.

18.

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.

Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK.

Am J Obstet Gynecol. 2008 Apr;198(4):477.e1-9; discussion 477.e9-10. doi: 10.1016/j.ajog.2007.12.028.

19.

PDGF receptors as targets in tumor treatment.

Ostman A, Heldin CH.

Adv Cancer Res. 2007;97:247-74. Review.

PMID:
17419949
20.

Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.

Kłosowska-Wardęga A, Hasumi Y, Åhgren A, Heldin CH, Hellberg C.

Melanoma Res. 2011 Feb;21(1):57-65. doi: 10.1097/CMR.0b013e32833faf4d.

PMID:
20975605

Supplemental Content

Support Center